Celularity Inc. (CELU)

CIK 0001752828 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
Latest Q3-2025 —
Q2-2025 8-K (2025-05-09) · 99.1
Q1-2025 —
FY-2024
FY-2024 —
Q3-2024 —
Q2-2024 8-K (2024-11-07) · 99.1  |  8-K (2024-10-25) · 99.1
Q1-2024 —
FY-2023 8-K (2024-05-21) · 99.1  |  8-K (2024-01-09) · 99.1
Q3-2023 —
Q2-2023 —
Q1-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statement of Operations and Comprehensive Loss
Consolidated Statements of Operations and Comprehensive Income (loss)
Condensed Consolidated Statements of Changes In Stockholders' (deficit) Equity (unaudited)
—
Condensed Consolidated Statements of Stockholders' Equity (deficit) (unaudited)
—
Consolidated Statements of Stockholders' (deficit) Equity
—
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Stockholders' (deficit) Equity (P)
—
Consolidated Statements of Cash Flows
Notes
Accrued Expenses and Other Current Liabilities
Asset Acquisition
Benefit Plan
—
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Debt
Equity
Fair Value of Financial Assets and Liabilities
Goodwill and Intangible Assets, Net
Income Taxes
—
Insider Trading Arrangements
Inventory
Investments Equity Securities
—
Leases
License and Distribution Agreements
Licensing Obligation
Nature of Business
Operating Leases
Pay Vs Performance Disclosure
Prepaid Expenses and Other Current Assets
Property and Equipment, Net
Related Party Transactions
Revenue
—
Revenue Recognition
Segment Information
Stock-based Compensation
Subsequent Events
Summary of Significant Accounting Policies
Transfers of Financial Assets